ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2246

Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews

Kaleb Michaud 1, Evo Alemao 2, Miroslawa Nowak 3, Rachel Bruce 4, Sarah Cantor 4, Carlijn Hintzen 5, Philip Mease 6, Kendra DeBusk2 and Alexis Ogdie 7, 1University of Nebraska Medical Center, Omaha, NE, 2Bristol-Myers Squibb, Princeton, 3Bristol-Myers Squibb, Princeton, NJ, 4IQVIA, New York, 5IQVIA, Amsterdam, Netherlands, 6Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 7University of Pennsylvania, Philadelphia

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ,

Session Information

Date: Tuesday, November 12, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease resulting in significant symptom burden.1 Over time and without adequate treatment, PsA can lead to disability and reduced patient quality of life.2 Fatigue is among the most common symptoms,1 but is complex and difficult to measure. The most burdensome symptoms that impact PsA patients need to be better understood in order to select patient reported outcomes (PRO) tools that adequately capture these concepts.

Objectives:

  1. Identify the signs and symptoms of PsA experienced by patients, with a focus on fatigue, and how the disease and its treatment(s) impact patients’ lives.
  2. Assess the content validity of select PRO instruments and items to measure fatigue.

Methods: Qualitative interviews were conducted among patients with PsA recruited through the FORWARD databank, all of which satisfy the ACR classification for PsA. The most frequently experienced symptoms and impacts of PsA and the degree to which they disturbed patients’ lives, were tabulated. Disturbance was evaluated on a scale from 0 (not at all) to 10 (greatly disturbs). Patients reporting fatigue were probed to describe the experience in their own words, and descriptors were recorded. Interviews were conducted and assessed on a rolling basis and recruitment continued until concept saturation was achieved. 

Results: Nineteen PsA patients were interviewed for this study. A core set of PsA symptoms were identified by nearly all patients and with moderate to high average disturbance ratings (Figure 1): joint pain, skin symptoms, stiffness, swollen/inflamed joints, and fatigue. The most salient impacts (Figure 2) were sleep disturbance, physical disability, effects on daily activities, and feelings of frustration. Most common descriptors of fatigue included “fatigue,” “tiredness,” “lack of energy,” “mental fatigue,” and “exhaustion.”

Conclusion: Salient symptoms were consistent with those previously reported, along with a broader range of symptoms and impacts, which included fatigue. In addition to physical disability, others such as sleep disturbance, frustration, and effect of daily activities were common high impact themes that emerged.


Figure 1


Figure 2

Disclosure: K. Michaud, FORWARD, The National Databank for Rheumatic Diseases, 3, Pfizer, 2, Pfizer & Rheumatology Research Foundation, 2, Rheumatology Research Foundation, 2, University of Nebraska Medical Center, 3; E. Alemao, Bristol Myers Squibb, 1, 3, 4; M. Nowak, Bristol-Myers Squibb, 1, 3, 4; R. Bruce, Eisai, Inc., 5; S. Cantor, None; C. Hintzen, None; P. Mease, Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Genentech, Janssen, Novartis, Pfizer, Roche, UCB, 2, 5, Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB, 8, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Abbvie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 5, Abbvie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB, 8, Abbvie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 2, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Leo, Merck, Novartis, Pfizer and UCB., 5, 8, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., and UCB, 2, Abbvie, Amgen, Brsitol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 5, Abbvie, Amgen, Brsitol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB, 8, Abbvie, Amgen, Brsitol Myers Squibb,Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 2, Amgen, 2, 5, 6, 8, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, GSK, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, and UCB, 5, BMS, 2, 5, 8, Boehringer Ingelheim, 2, 5, Boerhinger Ingelheim, 5, Bristol Myers Squibb, 2, 5, 8, Bristol Myers Squibb Co., 2, 5, 8, Bristol-Myers Squibb, 2, 5, 6, 8, Celgene, 2, 5, 6, 8, Celgene Corp., 2, 5, 8, CORRONA, 5, Eli Lilly, 2, 5, 8, Galapagos, 2, 5, 8, Genentech, 2, 5, 6, 8, Gilead, 2, 5, 8, Janssen, 2, 5, 6, 8, Janssen Inc, 2, 5, 8, Leo, 2, 5, 8, Lilly, 2, 5, 6, 8, Merck, 2, 5, 8, Novartis, 2, 5, 6, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, 6, Sun, 2, 5, SUN, 2, 5, Sun Pharma, 2, 5, Sun Pharmaceutical Industries, 2, 5, Sun Pharmaceutical Industries, Inc., 2, 5, 8, UCB, 2, 5, 6, 8, UCB Pharma, 2, 5, 8; K. DeBusk, Roche, 1, 3, 4, Bristol-Myers Squibb, 1, 3, 4, Seattle Genetics, 1, 3, 4; A. Ogdie, Pfizer, 2, 5, Abbvie, 5, 8, Amgen, 5, 8, BMS, 5, Celgene, 5, 8, Corrona, 5, Lilly, 5, Novartis, 5, Novartis, 7.

To cite this abstract in AMA style:

Michaud K, Alemao E, Nowak M, Bruce R, Cantor S, Hintzen C, Mease P, DeBusk K, Ogdie A. Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/symptoms-and-impacts-in-psoriatic-arthritis-findings-from-qualitative-patient-interviews/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/symptoms-and-impacts-in-psoriatic-arthritis-findings-from-qualitative-patient-interviews/